Key result
DOACs linked to ~58% fewer ischemic strokes and less hemoptysis vs VKAs in AF and lung cancer.
Why the study?
Anticoagulation in active lung cancer is complicated by high bleeding and thrombotic risks, and data on lung-cancer-specific safety, especially massive hemoptysis, remain limited.
Do DOACs reduce ischemic stroke and massive hemoptysis compared to VKAs in patients with active lung cancer and atrial fibrillation?
Population
2000 patients with active lung cancer and AF
Comparison
DOACs vs VKAs vs LMWH vs untreated cohort
Design
Retrospective observational study
Follow-up
12 months
Authors
Loading...
May support DOAC preference over VKAs in lung cancer with AF; leaves open need for randomized confirmation.
Observational (n=2,000)
Do DOACs reduce ischemic stroke and massive hemoptysis compared to VKAs in patients with active lung cancer and atrial fibrillation?
Hazard Ratio: 0.42 (95% CI 0.24–0.72)
p-value: p=0.002
DOACs provide superior stroke prevention and lower pulmonary bleeding risk compared to VKAs in patients with active lung cancer and atrial fibrillation.
Kaya et al. (2026) conducted an observational in active lung cancer and atrial fibrillation (n=2,000). Direct Oral Anticoagulants (DOACs) vs. Vitamin K Antagonists (VKAs) was evaluated on 12-month cumulative incidence of ischemic stroke (sHR 0.42, 95% CI 0.24-0.72, p=0.002). DOACs significantly reduced ischemic stroke risk compared to VKAs (sHR 0.42; 95% CI 0.24-0.72; P=0.002) and resulted in less massive hemoptysis (1.5% vs 5.0%) in active lung cancer and AF.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: